A user shared progress pictures after 15 months on 0.5 mg finasteride, reporting significant hair regrowth starting around 9 months. They no longer see the need for a hair transplant.
The user experienced significant hair regrowth using 1mg finasteride daily and Rogaine minoxidil 5% foam twice a day, along with vitamin D supplementation. They also managed stress through lifestyle changes like exercise, quitting nicotine, and improving sleep.
Vitamin E is suggested as beneficial for hair follicles. Some users question the dosage and effectiveness, while others share positive experiences with vitamins.
The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.
Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.
The user had a hair transplant in 2021 with 1600 grafts and is currently using finasteride, minoxidil, biotin, and collagen. They are considering another transplant in Turkey to address a bald spot and improve coverage in the front and middle.
PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.
The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
RU58841 is discussed as an effective hair loss treatment, with some users experiencing regrowth and reduced shedding, but concerns about safety and sourcing are raised. Users advise against purchasing from Amazon, recommending reputable sources and cautioning about potential side effects like cardiovascular issues.
Follica's preferred microneedling protocol for hair growth, which includes needle depth, frequency and movement parameters as well as the use of topical treatments such as minoxidil and finasteride.
The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.
A user shared a discount code for RU58841 from Anagen Inc, which some users find effective for hair loss without side effects. Another user expressed skepticism about the safety of RU58841 due to limited research.
.
This user experienced positive results from using a combination of minoxidil and finasteride, with no reported side effects after two months. Others have also shared their experiences with both short-term and long-term use of finasteride.
The conversation discusses androgenic alopecia (AGA) and its treatments, focusing on finasteride, minoxidil, and ketoconazole shampoo. Finasteride is recommended as essential for preventing further hair loss.
The conversation discusses the need for more support and awareness for Verteporfin research in hair loss treatment, emphasizing its potential benefits and quick implementation due to existing FDA approval. Users express skepticism due to past scams but acknowledge the importance of encouraging doctors to conduct trials.
A 19-year-old male using 1 mg finasteride every two days for hair loss reports no side effects and believes maintaining his current hair condition is progress. Some users see no difference in hair regrowth, attributing changes to lighting.
A user is asking about the effectiveness and dosage of RU58841 for hair loss, comparing it to Minoxidil and discussing its long-term use alongside Finasteride. They plan to use RU58841 and Finasteride for several years before potentially switching to GT20029.
PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.
The conversation discusses using Dr. Fox Hair Growth Spray, which contains 0.3% finasteride, 5% minoxidil, and 0.01% tretinoin. It suggests that a compound pharmacy might offer a cheaper alternative.
The user experienced significant hair growth and increased density after using 1.1mg finasteride for 4-5 weeks and switching from topical to oral minoxidil (3mg) for 3 weeks. They reported no shedding and were uncertain if the growth was due to the oral minoxidil or finasteride.
OP is experiencing significant hair loss despite GFC and PRP treatments and has abnormal lab results. They are advised to consult a hair-focused dermatologist for further evaluation.
The user experienced significant hair regrowth after 3.5 months of using finasteride 1 mg daily, despite stopping minoxidil after three weeks. They were surprised by the results and noted some weight gain but no significant side effects.
The conversation discusses whether finasteride would still be necessary if Verteporfin becomes a successful hair loss treatment. It also explores the sensitivity of transplanted hair to DHT and the potential for off-label use of Verteporfin post hair transplant.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.